Importantly, suspected adverse reactions to any medicine including unlicensed, counterfeit, or unregulated products can and should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app
Patients using Tirzepatide weight loss dosage have seen significant reductions in body weight, while those using Tirzepatide dose for diabetes experience improved insulin sensitivity and better blood sugar control
Average Weight Loss in the Orforglipron phase 3 ATTAIN-1 Trial Across the 72-week study period, participants: Lost up to 15% of their body weight at the highest dose At 36 mg: 54.6% lost 10%, 36.0% lost 15%, 18.4% lost 20% body weight (all higher than placebo)
What is your specific goal
What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care Brandon Aylward Oct 16, 2025 10 min read Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s)
